Shire Plc completed its acquisition of Baxalta Inc on 3 June to create a global company focused on developing drugs for rare diseases and other specialised conditions. The $32 billion deal comprises payments in both cash and Shire equity. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
